Return on Assets (ROA)
since 2005
Paying user area
Try for free
Illumina Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Illumina Inc., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net income (loss) attributable to Illumina stockholders1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 29, 2019 | = | 100 | × | ÷ | |||
| Dec 30, 2018 | = | 100 | × | ÷ | |||
| Dec 31, 2017 | = | 100 | × | ÷ | |||
| Jan 1, 2017 | = | 100 | × | ÷ | |||
| Jan 3, 2016 | = | 100 | × | ÷ | |||
| Dec 28, 2014 | = | 100 | × | ÷ | |||
| Dec 29, 2013 | = | 100 | × | ÷ | |||
| Dec 30, 2012 | = | 100 | × | ÷ | |||
| Jan 1, 2012 | = | 100 | × | ÷ | |||
| Jan 2, 2011 | = | 100 | × | ÷ | |||
| Jan 3, 2010 | = | 100 | × | ÷ | |||
| Dec 28, 2008 | = | 100 | × | ÷ | |||
| Dec 30, 2007 | = | 100 | × | ÷ | |||
| Dec 31, 2006 | = | 100 | × | ÷ | |||
| Jan 1, 2006 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$ in millions
The analysis of the financial data reveals several notable trends over the examined periods. The net income attributable to Illumina stockholders exhibits significant volatility in the earlier years, including a substantial loss of $278 million at the end of 2007, followed by recovery and generally positive earnings from 2008 onward. Noteworthy growth in net income occurs from 2013 to 2019, peaking at $1,002 million in 2019, before declining to $656 million in 2020.
Total assets demonstrate a consistent upward trajectory throughout the entire period. Starting from $101 million in early 2006, total assets increase steadily and substantially, reaching $7,585 million by the end of 2020. This growth indicates ongoing investment and expansion within the company.
Return on assets (ROA) shows a pattern that closely correlates with net income trends. Early negative ROA values correspond to the net losses experienced, with a low of -28.18% in 2007. From 2008 onward, ROA becomes positive, reflecting improved profitability. ROA peaks intermittently, with high values around 13.8% in 2017 and 13.7% in 2019, demonstrating efficient use of assets during these years. However, a decline to 8.65% in 2020 signals a reduction in asset profitability despite the continued asset base growth.
- Net Income Trends
- Initial volatility with losses transitioning to sustained profitability from 2008 forward.
- Peak net income observed in 2019, with a subsequent decline in 2020.
- Total Assets Growth
- Consistent increase across all periods, indicating expansion and asset accumulation.
- More than 70-fold increase from 2006 to 2020.
- Return on Assets (ROA)
- ROA moves from negative to positive values, aligning with improved net income performance.
- Peaks in 2017 and 2019 illustrate periods of high operational efficiency.
- Decline in 2020 suggests challenges in maintaining asset profitability despite growth.
Comparison to Competitors
Illumina Inc., ROA, long-term trends, comparison to competitors
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | |||||||||||||
| Dec 29, 2019 | |||||||||||||
| Dec 30, 2018 | |||||||||||||
| Dec 31, 2017 | |||||||||||||
| Jan 1, 2017 | |||||||||||||
| Jan 3, 2016 | |||||||||||||
| Dec 28, 2014 | |||||||||||||
| Dec 29, 2013 | |||||||||||||
| Dec 30, 2012 | |||||||||||||
| Jan 1, 2012 | |||||||||||||
| Jan 2, 2011 | |||||||||||||
| Jan 3, 2010 | |||||||||||||
| Dec 28, 2008 | |||||||||||||
| Dec 30, 2007 | |||||||||||||
| Dec 31, 2006 | |||||||||||||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Jan 1, 2017 | ||
| Jan 3, 2016 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Jan 1, 2012 | ||
| Jan 2, 2011 | ||
| Jan 3, 2010 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc., ROA, long-term trends, comparison to industry (health care)
| Illumina Inc. | Health Care | |
|---|---|---|
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Jan 1, 2017 | ||
| Jan 3, 2016 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Jan 1, 2012 | ||
| Jan 2, 2011 | ||
| Jan 3, 2010 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).